03:22 AM EDT, 03/28/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday their Dupixent, or dupilumab, drug was approved in Japan for the treatment of chronic obstructive pulmonary disease, or COPD, in adults.

COPD is a chronic respiratory disease that damages the lungs and causes lung function to decline.

The Japanese Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization for the drug based on data from a phase 3 trial. The study showed the product significantly reduced exacerbations and improved lung function compared with placebo, the companies said.